Research programme: anticancer immunotherapeutics - BrightPath Biotherapeutics

Drug Profile

Research programme: anticancer immunotherapeutics - BrightPath Biotherapeutics

Alternative Names: GRN-1301; Neoantigen therapeutics - BrightPath Biotherapeutics; Neoantigen-based cancer vaccine-BrightPath Biotherapeutics

Latest Information Update: 01 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator BrightPath Biotherapeutics
  • Class Antineoplastics; Cancer vaccines; Immunotherapies; Peptide vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Research Non-small cell lung cancer

Most Recent Events

  • 27 Oct 2017 National Cancer Center Tokyo and BrightPath Biotherapeutics agree to co-develop neoantigen vaccine for Cancer
  • 11 Jul 2017 BrightPath Biotherapeutics plans a phase I trial for Non-small cell lung cancer in Japan in 2018 (BrightPath Biotherapeutics website, July 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top